Advertisement

Topics

Abaloparatide Fracture Reductions Sustained in Osteoporosis

04:07 EDT 12 Sep 2017 | Medscape

Final results from the ACTIVExtend trial show sustained reductions with the osteoanabolic drug for 2 years after switching to a bisphosphonate, an effect that one expert commented is "impressive."
Medscape Medical News

Original Article: Abaloparatide Fracture Reductions Sustained in Osteoporosis

NEXT ARTICLE

More From BioPortfolio on "Abaloparatide Fracture Reductions Sustained in Osteoporosis"

Quick Search
Advertisement
 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...